The thought of a RS on any stock is a fear of any short-term trader. Do you get in now, get out, wait?. If you wait and the company announces the sale of the Dx division for $1B+ and a RS is not needed you miss out sitting on the sidelines.
For the long-term shareholder, it doesn't really matter. Be nice to see the company do a head fake and keep short-term traders on their toes.
Remember, as recently as last week in the presentation, Gerald said spinout or sale.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links